EMISPHERE TECHNOLOGIES INC

Form 8-K February 27, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

February 27, 2007

Emisphere Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	1-10615	13-3306985
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
765 Old Saw Mill River Road, Tarrytown, New York		10591
(Address of principal executive offices)		(Zip Code)
Registrant s telephone number, including a	area code:	914-347-2220
	Not Applicable	
Former nam	ne or former address, if changed since las	t report
Check the appropriate box below if the Form 8-K filing the following provisions:	g is intended to simultaneously satisfy th	e filing obligation of the registrant under any o

<u>Top of the Form</u> Item 8.01 Other Events.

On February 27, 2007, Emisphere Technologies, Inc. issued a press release announcing that Novartis Pharma AG and its development partner Nordic Bioscience have notified Emisphere of the initiation of a Phase III clinical trial for the treatment of osteoporosis with an oral form of salmon calcitonin (referred to as SMC021), a new drug candidate, using Emisphere's eligen® delivery technology. As a result of the initiation of the trial, Emisphere will receive a milestone payment from Novartis.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1- Press release of Emisphere Technologies, Inc. dated February 27, 2007.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Emisphere Technologies, Inc.

February 27, 2007 By: Lewis H. Bender

Name: Lewis H. Bender

Title: President and Chief Executive Officer

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release of Emisphere Technologies, Inc. dated February 27, 2007